Mountain Crest Acquisition Corp. II
MCADR
NASDAQ1.03
USD
+0.01
- -
CIK
0001832415
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
232.26
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Suying Liu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 311 West 43rd Street New York City NY United States of America
- IPO Date
- Mar 15, 2021
- CIK
- 0001832415
- Similar Companies
- Business
- Mountain Crest Acquisition Corp. II (MCADR) operates as a blank check company whose primary business is to pursue a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a focus on operational targets primarily in North America; it currently maintains no significant independent operations. The company, founded in 2020 and headquartered in New York, New York, went public via an initial public offering in January 2021, raising approximately $57.5 million in proceeds held in trust, and offered common stock under the ticker MCAD alongside rights under MCADR. Its core offerings consist solely of these special purpose acquisition activities targeting sectors such as financial services and shell companies without predefined industry restrictions. In a major development, Mountain Crest Acquisition Corp. II completed a reverse merger with Better Therapeutics, Inc., a prescription digital therapeutics company focused on cognitive behavioral therapy for cardiometabolic diseases including type 2 diabetes via its lead product BT-001, on October 28, 2021, generating about $70 million in gross proceeds including a $50 million private investment in public equity and resulting in the combined entity trading as Better Therapeutics under the ticker BTTX on Nasdaq starting October 29, 2021. Subsequent legal proceedings, including a class action settlement related to the merger preliminarily approved by the Delaware Court of Chancery on July 25, 2025 with a final hearing scheduled for October 24, 2025, represent the most recent significant developments for legacy MCADR rights holders. MCADR rights continue to trade separately at approximately $1.03 as of late 2025, reflecting post-merger legacy status without new operational activities or expansions.